Alzheimer disease
Conditions
Interventions
The open-label, 12-month study evaluated the treatment effect and response of galantamine in Alzheimers patients who had previously failed to benefit from the treatment with donepezil. The patients be
Sponsors
Department of Neuropsychiatry, Keio University School of Medicine,
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A diagnosis of probable AD according to the National Institute of Neurological and Communication Disorders and Stroke Alzheimer Disease and Related Disorders Association criteria, very mild to mild , moderate functional severity, reliable informed consent could be obtained from the patient and or his her relatives, the chief caregiver is the patients family ,the patients Mini Mental State Examination score was less than 11,poor response was defined as the score of MMSE or ADASJ cog over the half of a year during the treatment with donepezil.
Exclusion criteria
Exclusion criteria: either previous history or now taking other choline inhibitors (galantamine, rivastigmine) and memantine, taking antipsychotic or antidepressant medication,there was a previous history of mental illness or substance abuse,either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings , the patient has pacemaker, other findings in terms with the aims of this study, illness or substance abuse,either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings , the patient has pacemaker, other findings in terms with the aims of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| multi-modal neuroimaging analysis 1 Structural neuroimaging analysis Brain MRI: voxel-based morphometry (VBM) diffusion tensor imaging (DTI) 2 Functional neuroimaging analysis single photon emission computed tomography (SPECT) near-infrared spectroscopy (NIRS) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Cognitive assessment Mini-Mental State Examination (MMSE) Clock drawing test The Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog) Frontal assessment battery (FAB) 2 Behavior assessment Clinical assessment for spontaneity (CAS) Neuropsychiatry Inventory Questionnaire (NPI-Q) Quality of life-Alzheimer's Disease (QOL-AD) Scale | — |
Countries
Japan
Contacts
Public ContactShutaro Nakaaki
Keio University School of Medicine Department of Neuropsychiatry, Laboratory of Aging, Behavior and Cognition
Outcome results
None listed